Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma Sponsors Educational Website about Tuberculosis (TB) in Conjunction with World TB Day
March 26, 2007

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that it has sponsored the website,, to educate the public about Tuberculosis (TB).

“Many people believe that Tuberculosis was a disease of the past,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “In fact, Tuberculosis, especially the drug-resistant XDR-TB strain, is a major concern for many developing countries that experience high rates of HIV infections,” he added.

The launch of coincides with World Tuberculosis Day, which was held on March 24, 2007. The website features information about Tuberculosis: its symptoms, diagnosis and treatments, as well as a list of organizations dedicated to eradicating the disease.

“New Tuberculosis (TB) infections are occurring at a rate of one per second and the disease accounts for over a million deaths each year,” explained Neil Roth, President of Designer Diagnostics. “We believe that one of the primary strategies for preventing the spread of the disease and saving patient lives is to educate the public about early detection and recognizing its symptoms,” he added.

In January, Designer Diagnostics announced the positive results of an in-vitro analysis of its Tuberculosis (TB) test kit. Normal culturing methods can take as long as 10 weeks to produce results, whereas Designer Diagnostics test kits showed similar results within 10 days.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The launch of should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet

June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics